ProImmune and UTMB Join Forces to Tackle Emerging Infectious Diseases
A new collaboration between ProImmune, Ltd. and the University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL) promises to accelerate research into high-consequence infectious diseases. The partnership will leverage ProImmune’s innovative Ankyron technology to study viral proteins under high-containment conditions, potentially leading to breakthroughs in vaccine and therapeutic development.
The Rise of Ankyron Technology
Ankyrons represent a novel approach to studying infectious diseases. These small, single-domain binding reagents are engineered for high affinity and specificity to diverse protein targets. Unlike traditional antibody-based methods, Ankyrons are generated in vitro, eliminating the need for animal immunization and significantly speeding up the research process. This is particularly crucial when dealing with rapidly emerging pathogens.
Currently available for 60 pathogens and disease vectors, Ankyrons can be rapidly developed for new and emerging disease targets. This adaptability positions them as a powerful tool in the fight against future pandemics.
Focus on High-Containment Pathogens
The collaboration will initially focus on validating Ankyrons for several pathogens of major global health concern: Bundibugyo virus, Zaire ebolavirus, Sudan ebolavirus, Reston ebolavirus, Human Enterovirus 71, and Mpox virus. These studies will be conducted in the laboratory of Dr. Courtney Woolsey at GNL, a facility equipped to handle pathogens under maximum-containment conditions (BSL-4).
“Ankyrons and our powerful automated high throughput parallel discovery platform are particularly well suited for demanding research environments such as emerging infectious diseases, enabling detection and interrogation of viral proteins and study of multiple rapidly emerging infectious diseases simultaneously,” says Nikolai Schwabe, Chief Executive Officer of ProImmune, Ltd.
Strengthening Pandemic Preparedness: A Look Ahead
This collaboration highlights a growing trend towards proactive pandemic preparedness. The ability to rapidly identify and study viral proteins is essential for developing effective countermeasures. Ankyron technology, combined with the expertise of institutions like UTMB GNL, represents a significant step forward in this effort.
The focus on understanding viral protein function, immune dysregulation, and tissue-specific responses will inform the next generation of vaccines and therapeutics. This targeted approach is more efficient and potentially more effective than traditional, broad-spectrum strategies.
The Future of Infectious Disease Research
Several factors are driving innovation in infectious disease research:
- Rapid pathogen evolution: Viruses and bacteria are constantly evolving, requiring continuous monitoring and adaptation of research tools.
- Globalization: Increased travel and trade facilitate the rapid spread of infectious diseases across borders.
- Climate change: Shifting environmental conditions can create new opportunities for pathogens to emerge and spread.
Technologies like Ankyrons, alongside advancements in genomics, proteomics, and bioinformatics, are empowering researchers to address these challenges more effectively. Expect to see increased investment in research focused on early detection, rapid response, and the development of broadly protective vaccines and therapeutics.
Frequently Asked Questions
What are Ankyrons? Ankyrons are small, engineered binding reagents used to detect and study proteins, particularly those from viruses and other pathogens.
What is BSL-4? BSL-4 (Biosafety Level 4) is the highest level of biocontainment used in laboratories working with dangerous and exotic microorganisms.
Why is this collaboration important? This collaboration combines cutting-edge technology with world-class expertise to accelerate research into emerging infectious diseases and strengthen pandemic preparedness.
Where can I learn more about ProImmune’s Ankyron technology? Visit ProImmune’s Ankyron page for detailed information.
What are the benefits of using Ankyrons compared to traditional methods? Ankyrons offer faster development times, eliminating the need for animal immunization, and can be rapidly adapted to new and emerging disease targets.
Want to stay informed about the latest advancements in infectious disease research? Explore ProImmune’s news archive for updates and insights.
